• Have any questions?
  • +1-888-INTL-SOS
  • support@globalreachhealth.com
  • Home
  • About
    • About
    • Licensure and Compliance
    • Company Brochure
    • Leadership
    • Careers
  • Divisions
    • Global Reach Rx
      • Service Countries
      • Pharmacy Discount Card
    • Global Reach Rx USA
    • Global Reach Arabia
    • Global Reach Pharma
    • Global Reach Financial Services
    • Global Reach Technology Services
    • Global Reach Miracle Foundation
    • Global Reach Health Clinic
    • Now Salud
  • Member Savings Programs
    • Wellevate Store
    • Pharmacy Discount Card
    • American Vaccine
    • Global immunization
  • News
  • Contact
  • Accessibility
  • Cookie Policy
  • Contact Us
  • Legal Disclaimer
  • Privacy Policy
  • Security
  • Sitemap
✕

News

  • Home
  • News
  • Filter by
  • Categories
  • Tags
  • Authors
  • Show all
  • All
  • Global Reach Health News
  • Pharmaceutical News
  • Uncategorized
  • All
  • Global healthcare
  • Global Reach Health
  • Health
  • Insurance
  • International Health Insurance
  • International Medical Assistance
  • International Medical Insurance
  • pharmace
  • Pharmaceutical
  • Pharmaceutical News
  • Pharmacy Benefits Management
  • Technology
  • All
  • GlobalReach Health
October 10, 2024

OTHER ANNOUNCEMENTS AND ARTICLES

About 6% of U.S. Adults Have ADHD, Drug Shortages Are Affecting Treatment
Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 10, 2024.
By Ernie Mundell HealthDay Reporter
September 30, 2024

GENERIC DRUG APPROVALS

September 30, 2024 - Drospirenone Tablets 4mg
Approved: September 30, 2024 - Lupin Ltd.
Indicated for: Contraception
Generic for: Slynd
September 30, 2024

FDA Approves Otulfi™, a Biosimilar to Stelara®

September 30, 2024 – Fresenius Kabi, and Formycon AG, announced the U.S. Food and Drug Administration (FDA) approved OtulfiTM (ustekinumab-aauz), its ustekinumab biosimilar referencing Stelara®.
September 27, 2024

FDA Approves Flyrcado Radioactive Diagnostic for Enhanced Diagnosis of CoronaryArtery Disease

September 27, 2024 GE HealthCare announced the U.S. Food and Drug Administration (FDA) granted approval of Flyrcado (flurpiridaz F-18) injection
September 26, 2024

FDA is Alerting Patients and Health Care Professionals About the Voluntary Withdrawal of Oxbryta from the Market Due to Safety Concerns

September 26, 2024 – The FDA is alerting patients, caregivers, and health care professionals that Oxbryta (voxelotor) is being voluntarily withdrawn from the market by the manufacturer
September 26, 2024

FDA Approves Cobenfy, a First-In-Class Muscarinic Agonist for the Treatment ofSchizophrenia in Adults

September 26, 2024 Bristol Myers Squibb announced the U.S. Food and Drug Administration (FDA) approved Cobenfy (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults.
September 25, 2024

FDA Approves Aqneursa for the Treatment of Niemann-Pick Disease Type C

September 25, 2024 - IntraBio Inc. announced the U.S. Food and Drug Administration (FDA) approved Aqneursa (levacetylleucine) for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15kg
September 20, 2024

Gilead Issues Voluntary Nationwide Recall of One Lot of Veklury (Remdesivir) for Injection 100mg/vial Due to the Presence of a Glass Particle

September 20, 2024 – Gilead Sciences, Inc. announced it is issuing a voluntary recall of one lot of Veklury (remdesivir) for Injection 100mg/vial, to the consumer level.
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101
Next page

Search

✕

Global Healthcare News

Keep up-to-date with global healthcare news including pharma, medical assistance, international insurance and technology.

Latest posts

  • 0
    OTHER ANNOUNCEMENTS AND ARTICLES
    October 10, 2024
  • 0
    GENERIC DRUG APPROVALS
    September 30, 2024

Categories

  • Global Reach Health News
  • Pharmaceutical News
  • Uncategorized

Tags

Global healthcare Global Reach Health Health Insurance International Health Insurance International Medical Assistance International Medical Insurance pharmace Pharmaceutical Pharmaceutical News Pharmacy Benefits Management Technology

About Global Reach Health

Global Reach Health is a diverse group of global healthcare divisions and partners delivering healthcare solutions across the globe.

Global Reach Health administrates five separate divisions to deliver seamless cross border healthcare solutions and services for a myriad of clients around the globe including insurers, pharmacies, hospitals and clinics, assistance firms, cost containment companies, third party administrators plus public entities and private corporations.

Important Links

  • Accessibility
  • Cookie Policy
  • Contact Us
  • Legal Disclaimer
  • Privacy Policy
  • Security
  • Sitemap

Recent posts

  • 0
    OTHER ANNOUNCEMENTS AND ARTICLES
    October 10, 2024
  • 0
    GENERIC DRUG APPROVALS
    September 30, 2024


© 2019 - 2025 Global Reach Health. All Rights Reserved.
Contact